At ASH 2025, Prof. Jeff Sharman from the Willamette Valley Cancer Research Institute shares key clinical insights on mosunetuzumab, focusing on its safety, efficacy, and durability of response, particularly in elderly patient populations who may not be ideal candidates for intensive chemotherapy.
In this on-site interview, Prof. Sharman discusses durable treatment effects, the achievement of MRD negativity, and the potential for bispecific antibodies like mosunetuzumab to move beyond traditional R-CHOP–based approaches and help redefine treatment strategies in lymphoma.
Watch the full interview to explore how evolving immunotherapies are shaping the future of hematologic care.
